{"schema_version":"secwatch.filing_event.v1","accession":"0001503274-26-000011","form_type":"8-K","ticker":"QTRX","cik":"0001503274","company_name":"Quanterix Corp","filed_at":"2026-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.248820+00:00","generated_at":"2026-05-15T22:37:24.685426+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Quanterix Q4 revenue $43.9M (+25% YoY); guides 2026 rev $169-174M, cash flow breakeven H2","bullets":["Q4 revenue $43.9M vs $35.2M prior year (+25%); full-year revenue $138.9M (+1% YoY).","GAAP gross margin 45.7% (Q4) and 46.8% (FY); adjusted gross margin 50.0% (Q4) and 47.3% (FY).","Adjusted EBITDA loss of $7.9M in Q4 and $44.9M for FY; cash balance $121.6M.","Initial 2026 guidance: revenue $169-174M, adjusted gross margin 49-53%, cash ~$100M year-end.","Filed 510(k) for Alzheimer's blood test; CMS set reimbursement rate of $897 for LucentAD Complete."],"urls":{"canonical":"https://secwatch.observer/filing/0001503274-26-000011","json":"https://secwatch.observer/filing/0001503274-26-000011.json","markdown":"https://secwatch.observer/filing/0001503274-26-000011.md","text":"https://secwatch.observer/filing/0001503274-26-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503274/000150327426000011/0001503274-26-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503274/000150327426000011/qtrx-20260302.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:37:24.685426+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}